Visual Dysfunction in Diabetes (eBook)
XV, 379 Seiten
Humana Press (Verlag)
978-1-60761-150-9 (ISBN)
An exciting contribution to the field, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement is designed with two overriding objectives: to help readers understand the impact of vision impairment in people living daily with diabetes rather than considering diabetic retinopathy solely as a medical problem, and to explore what we know and don't know about the ways diabetes affect the eye. With the plethora of new information being generated, there are still a series of fundamental questions that must be addressed if effective treatments for diabetic retinopathy are to be found and applied. Developed by a renowned group of authorities, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers responses and context for a range of questions, such as: do metabolic factors beyond glucose contribute to vision-threatening diabetic retinopathy? If so, how do these lead to vision impairment? Is diabetic retinopathy a response to systemic metabolic abnormalities or are there unique ocular problems related to insulin resistance? What is the relationship between the neural, vascular, and inflammatory abnormalities in diabetic retinopathy? Do they represent a pathological cascade induced sequentially or simultaneous responses to one or more metabolic perturbations? The authors note that if we do not address these types of questions, it is possible that the long process of developing new therapeutic
s will target only one arm of the pathology and leave the retina open to damaging consequences of the others. State-of-the-art, comprehensive, and an invaluable addition the research and clinical literature, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers guidance and a significant step toward new scientific approaches that can lessen the devastating vision impairment associated with diabetes.An exciting contribution to the field, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement is designed with two overriding objectives: to help readers understand the impact of vision impairment in people living daily with diabetes rather than considering diabetic retinopathy solely as a medical problem, and to explore what we know and don't know about the ways diabetes affect the eye. With the plethora of new information being generated, there are still a series of fundamental questions that must be addressed if effective treatments for diabetic retinopathy are to be found and applied. Developed by a renowned group of authorities, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers responses and context for a range of questions, such as: do metabolic factors beyond glucose contribute to vision-threatening diabetic retinopathy? If so, how do these lead to vision impairment? Is diabetic retinopathy a response to systemic metabolic abnormalities or are there unique ocular problems related to insulin resistance? What is the relationship between the neural, vascular, and inflammatory abnormalities in diabetic retinopathy? Do they represent a pathological cascade induced sequentially or simultaneous responses to one or more metabolic perturbations? The authors note that if we do not address these types of questions, it is possible that the long process of developing new therapeutics will target only one arm of the pathology and leave the retina open to damaging consequences of the others. State-of-the-art, comprehensive, and an invaluable addition the research and clinical literature, Visual Dysfunction in Diabetes: The Science of Patient Impairment and Improvement offers guidance and a significant step toward new scientific approaches that can lessen the devastating vision impairment associated with diabetes.
IntroductionDiabetic Retinopathy – what we know, don’t know, and need to know – Tom GardnerLiving with Diabetic RetinopathyCh. 1 A Patient’s viewpoint: Heather StuckeyCh. 2 What patients with diabetes see—and don’t see: subjective and objective visual functionchanges - Shelly BoydCh. 3 How do I know I have diabetic retinopathy – a clinician’s view? - David QuillenPrevalence, Public Awareness, and Screening MethodsCh. 4 Epidemiology & Economics - John JavittCh. 5 Correlation between the presence and severity of diabetic retinopathy in families with diabetes- Victor GonzalezCh. 6 Increasing public awareness of the diabetes endemic – Ian ConstableCh. 7 Nutrition and diabetes– David NathanCh. 8 Diabetic retinopathy screening – progress and complications - Peter Scanlon Diagnosing Diabetic Retinopathy Ch. 9 Measurements of retinal blood flow, vascular leakage, and oxygenation – Einer StefanssonCh. 10 Optical imaging - Confocal microscopy to detect retinal vasculature – Martin FriedlanderCh. 11 Structural imaging – OCT – M. LarsenCh. 12 Functional imaging - ERG - Anthony Adams How Diabetes Affects the EyeCh. 13 Clinical phenotypes (reclassification) – J. Cunha-VazCh. 14 Vascular changes – David Antonetti & Tom Gardiner (Belfast)Ch. 15 Neuronal changes - Alistair Barber/Greg JacksonCh. 16 Inflammatory changes - Mark TsoCh. 17 Other Ocular Complications of Diabetes - Shoja MR New Approaches to Diabetic RetinopathyCh. 18 New insights in the pathogenesis of diabetic retinopathy using a proteomic approach – Retina -Quin GGCh. 19 Vitreous proteomics – Ed FeenerCh. 20 Genomics - Bill FreemanCh. 21 Genome-wide linkage analyses to identify Loci for diabetic retinopathy - Kang Zhang (Utah)Risk FactorsCh. 22 Diabetic retinopathy correlates with increased incidence of cardiovascular events -Cheung NCh. 23 Pregnancy and rate of progression of diabetic retinopathy – Sheth BP Molecular Mechanisms that Could Trigger Visual Dysfunction in DiabetesIntroduction - Tom GardnerCh. 24 Inflammation in the early pathogenesis of diabetic retinopathy —beauty and beast. - Chris Norbury (Hershey)Ch. 25 Oxidative stress and diabetic retinopathy. - Catherine WhitesideCh. 26 Glucose induced cellular signaling in diabetic retinopathy – Chakrabarti SCh. 27 The AGE/RAGE axis in early diabetic retinopathy - Schmidt AMCh. 28 Proteases and the retinal vasculature (and maybe the whole retina!) – Arup Das.Ch. 29 IGFBP3 and retinal vessel growth. Smith LECh. 30 PEDF, VEGF, CTGF review – JX MaCh. 31 A decrease in the expression of somatostatin is an early event in diabetic retinopathy -Carrasco ECh. 32 Connective tissue and connective tissue growth factor in diabetic retinopathy - SchlingemannROCh. 33 Molecular regulation of endothelial cell tight junctions and the blood retinal barrier - AntonettiDACh. 34 Pericytes and diabetic retinopathy - Puro DGCh. 35 Leukostasis - Adamis, APCh. 36 Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes. -Khalfaoui T, Ch. 37 Azurocidin as a Permeability Factor in the Retina - Hafezi-Moghadam ACh. 38 Retinal arteriolar hemodynamic response to a combined isocapnic hyperoxia and glucoseprovocation in early sight-threatening diabetic retinopathy. - Devenyi RG.Ch. 39 Urinary 8-hydroxydeoxyguanosine (8-OHdG) levels in diabetic retinopathy patients. - SteveAbcouwerCh. 40 Tyrosine nitration in the molecular mechanisms of diabetic retinopathy. - Crabb JWLimiting Vision Loss - Experimental TherapiesIntroduction - Tom GardnerVascular ControlCh. 41 Ranibizumab for macular edema in diabetes – Quan Dong NguyenCh. 42 Bevacizumab for PDR - Qin HCh. 43 Capillary degeneration in the early stages of diabetic retinopathy. Kern TSCh. 44 Renin-angiotensin system in the eye - Jennifer Wilkinson-BerkaCh. 45 Statins and the BRB –Ruth Caldwell Neuronal ControlCh. 46 Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in amouse model of disease. Lahdenranta JCh. 47 Intravitreal Injection of Erythropoietin Protects both Retinal Vascular and Neuronal Cells inEarly Diabetes - Zhang J and Xu GTInflammatory ControlCh. 48 Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabeticretinopathy. Sawada NCh. 49 Ruboxistaurin shows promise as an oral treatment for diabetic retinopathy - Clarke M, DodsonPM.Ch. 50 Intravitreal triamcinolone acetonide for diabetic retinopathy - Jonas JBCh. 51 Aptamers that bind PDGF-B are a potential treatment for proliferative retinopathies. Akiyama HCh. 52 Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy - Lin JRegenerative ApproachesCh. 53 Islet Cell/stem cell transplantation - Warnock GL (Canada)Future DirectionsCh. 54 How do we improve the translational research process? What do we need to know? BarbaraAraneo Conclusion – Tom Gardner
| Erscheint lt. Verlag | 16.12.2011 |
|---|---|
| Reihe/Serie | Ophthalmology Research | Ophthalmology Research |
| Zusatzinfo | XV, 379 p. 72 illus., 51 illus. in color. |
| Verlagsort | Totowa |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Augenheilkunde |
| Medizinische Fachgebiete ► Innere Medizin ► Diabetologie | |
| Schlagworte | Diabetes • ERGs • Microvascular • Retinal Neovasularization • Retinopathy • Vascular Permeability |
| ISBN-10 | 1-60761-150-3 / 1607611503 |
| ISBN-13 | 978-1-60761-150-9 / 9781607611509 |
| Haben Sie eine Frage zum Produkt? |
PDF (Wasserzeichen)Größe: 7,5 MB
DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasserzeichen und ist damit für Sie personalisiert. Bei einer missbräuchlichen Weitergabe des eBooks an Dritte ist eine Rückverfolgung an die Quelle möglich.
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
